OncoMatch/Clinical Trials/NCT07155525
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
Is NCT07155525 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2) for pancreatic cancer.
Treatment: Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2) — This is a single-center, randomized controlled trial comparing the efficacy of pancreaticojejunostomy with modified N-butyl-2-cyanoacrylate(Glubran® 2) versus standard pancreaticojejunostomy without cyanoacrylate in preventing postoperative pancreatic fistula (POPF) in patients undergoing pancreaticoduodenectomy with soft pancreatic texture. The primary endpoint is the incidence of postoperative pancreatic fistula at 30 days post-surgery, as defined by the International Study Group on Pancreatic Fistula (ISGPF) criteria.Secondary outcomes include surgical complications and length of hospital stay. The study will enroll approximately 194 patients at a single center.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Cholangiocarcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: pancreatic surgery or pancreatic anastomosis
Previous pancreatic surgery or pancreatic anastomosis
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL; Absolute neutrophil count ≥ 1,500/μL; Platelet count ≥ 100,000/μL
Kidney function
Serum creatinine ≤ 1.5 times upper limit of normal
Liver function
Total bilirubin ≤ 3 times upper limit of normal; ALT ≤ 5 times upper limit of normal
Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count ≥ 1,500/μL Platelet count ≥ 100,000/μL Total bilirubin ≤ 3 times upper limit of normal Alanine transaminase (ALT) ≤ 5 times upper limit of normal Serum creatinine ≤ 1.5 times upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify